Concept of 505 (B) (2) Application: Benefits and Challenges

Chaitanya Prasad K ； Prabodh M ； Ashish S ； Suthakaran R

《International Journal of Drug Regulatory Affairs》 2卷2期 (2014/06) Pp. 16-20

並列摘要

A 505 (b) (2) application is a new drug application (NDA) delineated in section 505 (b) (2) of the Federal Food, Drug, and Cosmetic Act.505 (b) (2) application is one that one or a lot of the investigations relied upon by the applicant for approval ＂were not conducted by or for the applicant and has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Section 505 (b) (2) was added to FFDC Act by the Drug price competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The applicant will depend on either revealed literature or agency's findings of an antecedent approved drug. This approval route was designed to encourage innovation and to eliminate expensive and long duplicative clinical studies.

並列關鍵字

ANDA ； Clinical Trials ； CFR ； Exclusivity ； FFDC Act ； Hatch Waxman Act ； 505 (b) (1) ； NDA ； NME